Fenofibrate is not a substrate for CYP 3A4. Version: 11.01.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. In this case, Fenofibrate 67 mg capsules should be used, e.g. Side effects After using Fenofibrate Mylan Product description. Peak plasma concentration occurs after a mean period of 5 hours following dosing.Mean plasma concentration is 15μg/ml for a daily dosage of 200 mg of micronised fenofibrate, equivalent to 3 capsules of 67 mg micronised fenofibrate. The absorption of fenofibrate is increased when administered with food.Mean plasma concentration is 15 µg / ml for a daily dosage of 200 mg of micronised fenofibrate.Fenofibric acid is strongly bound to plasma albumin (more than 99%): it can displace antivitamin K compounds from the protein binding sites and potentiate their anticoagulant effect.After oral administration, fenofibrate is rapidly hydrolysed by esterases to the active metabolite fenofibric acid.No unchanged fenofibrate can be detected in the plasma. In the majority of cases no overdose symptoms were reported. Muscle toxicity should be suspected in patients presenting diffuse myalgia, myositis, muscular cramps and weakness and/or marked increases in CPK (levels exceeding 5 times the normal range). Betnovate RD Ointment. Apolipoprotein–A and apolipoprotein–B levels are altered in parallel with HDL and LDL and VLDL levels respectively.Extravascular deposits of cholesterol (tendinous and tuberous xanthoma) may be markedly reduced or even entirely eliminated during fenofibrate therapy.Plasma uric acid levels are increased in approximately 20 % of hyperlipidaemic patients, particularly in those with type IV phenotype.The uricosuric effect of fenofibrate leading to the reduction in uric acid levels of approximately 25% should be of additional benefit in those dyslipidaemic patients with hyperuricaemia. Follow all directions on your prescription label and read all medication guides or instruction sheets. 2 Fenofibrate 67 mg capsules daily for creatinine clearance levels of <60 ml/min and 1 Fenofibrate 67 mg capsule daily for creatinine clearance levels of <20 ml/min. jaundice, pruritus), and diagnosis is confirmed by laboratory testing, fenofibrate therapy should be discontinued.

No hepatic microsomal metabolism is involved. When symptoms indicative of hepatitis occur (e.g. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. When suggestions are available use up and down arrows to review and ENTER to select. The incidence of this disorder increases in cases of hypoalbuminaemia and previous renal insufficiency. The FIELD study reported that, if treated with fenofibrate, there would have been 1.1 fewer first laser treatments performed per 100 patients in those without pre-existing retinopathy (number needed to treat [NNT] 90). sun lamp)Musculoskeletal, connective tissue and bone disordersmuscle toxicity (diffuse myalgia, myositis, muscular cramps and weakness) (see section 4.4)General disorders and administration site conditions* In the FIELD-study, a randomized placebo-controlled trial performed in 9795 patients with type 2 diabetes mellitus, a statistically significant increase in pancreatitis cases was observed in patients receiving fenofibrate versus patients receiving placebo (0.8% versus 0.5%; p = 0.031). • Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia.Secondary causes of hyperlipidemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment, alcoholism, should be adequately treated before fenofibrate therapy is considered. The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate < 60 … Chlorocresol (preservative) 4. The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. Patients co-administered fenofibrate and CYP2C19, CYP2A6, and especially CYP2C9 metabolised drugs with a narrow therapeutic index should be carefully monitored and, if necessary, dose adjustment of these drugs is recommended.No proven clinical interactions of fenofibrate with other drugs have been reported, although in vitro interaction studies suggest displacement of phenylbutazone from plasma protein binding sites. When symptoms indicative of hepatitis occur (e.g. The recommended initial dose is one capsule taken daily during a main meal.

The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate < 60 mL/min/1.73 (see Patients with renal impairment).The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. It is recommended that transaminase levels are monitored every three months during the first twelve months of treatment and thereafter periodically. If overdose is suspected, treat symptomatically and institute appropriate supportive measures as required. This site uses cookies. HDL–cholesterol levels are frequently increased. Fenofibrate plus simvastatin therapy did not show any significant differences compared to simvastatin monotherapy in the composite primary outcome of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death (hazard ratio [HR] 0.92, 95% CI 0.79-1.08, p = 0.32 ; absolute risk reduction: 0.74%). Company: GlaxoSmithKline (Ireland) Ltd.